Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.51 |
| ▸ | MAOA | P21397 | 7/20 | 0.51 |
| ▸ | ALDH1A2 | O94788 | 3/20 | 0.47 |
| ▸ | ALDH1A3 | P47895 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5438632 | 0.95 | MAOB (0.55) | MAOBMAOAALDH1A2ALDH1A3MAPT | |
| SCHEMBL5429798 | 0.90 | MAOB (0.53) | MAOBMAOAALDH1A2ALDH1A3TP53 | |
| SCHEMBL5431431 | 0.89 | MAOB (0.54) | MAOBMAOAALDH1A2ALDH1A3MEN1 | |
| SCHEMBL5434358 | 0.88 | MAOB (0.47) | MAOBMAOAALDH1A2ALDH1A3 | |
| SCHEMBL5432180 | 0.86 | MAOB (0.43) | MAOBMAOAALDH1A2ALDH1A3ALDH1A1 | |
| SCHEMBL5437170 | 0.84 | MAOB (0.58) | MAOBMAOAALDH1A2ALDH1A3ALDH1A1 | |
| SCHEMBL5431372 | 0.84 | MAOA (0.43) | MAOBMAOAALDH1A2ALDH1A3KMT2A | |
| SCHEMBL5429219 | 0.83 | ALDH1A2 (0.40) | MAOBMAOAALDH1A2ALDH1A3KMT2A | |
| SCHEMBL5437816 | 0.83 | ALDH1A3 (0.68) | ALDH1A2ALDH1A3TP53ALDH1A1 | |
| SCHEMBL5438225 | 0.82 | MAOB (0.41) | MAOBMAOAALDH1A2ALDH1A3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | claimed |
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | TRPV1, TRPV2, TRPV4 | MAOB 3067/4885MAOA 3455/4885ALDH1A2 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.